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Abstract 
Attention-deficit/hyperactivity disorder (ADHD) is one of the most common psychiatric 
disorders in children and adolescents, with up to 5% affected worldwide. Twin and family 
studies on ADHD show its high familiality with heritability estimated around 70%, but, to 
date, no specific polymorphism or gene was found to be specifically affected. 
Psychostimulants (amphetamine, methylphenidate) and non-psychostimulants (atomoxetine) 
are used successfully in ADHD therapy, but many of their mechanisms of action and their 
adverse effects are not yet fully understood. Therefore, both genetic findings and therapeutic 
interventions should be further investigated. One easy platform for such studies are in vitro 
analyses, which encompass neuronal cell culture studies, transfections of genetic constructs, 
binding and electrophysiology analyses. In this review, different methods will be referred in 
particular to ADHD findings, and new techniques will be mentioned for future studies of drug 
or genetic effects in vitro.  
 
Key Words: Atomoxetine, attention-deficit hyperactivity disorder, cell culture, 
electrophysiology, methylphenidate, neuron  
J. Neural Transm. Review        JNT-D-12-00081 Grünblatt et al. 2012 
 3 
Introduction 
Attention-deficit/hyperactivity disorder (ADHD) is one of the most common psychiatric 
disorders in children and adolescents, with up to 5% affected worldwide and with similar 
prevalence rates throughout different cultural settings (Polanczyk et al. 2007). ADHD is 
characterised as a clinically heterogeneous neurodevelopmental syndrome by the constitutive 
development of inappropriate levels of inattention, hyperactivity, and impulsiveness. The 
syndromal dimensions of inattention and enhanced impulsivity are increasingly recognised as 
highly persistent into adulthood and are associated with considerable risk for psychiatric co-
morbidity such as depression, substance abuse disorder, and failure in psychosocial adaptation 
(Jacob et al. 2007). 
State-of-the-art treatments for ADHD include parental training, psychotherapeutic-
behavioural therapy, and social interventions. According to the European Network for 
Hyperkinetic Disorders (EUNETHYDIS) Guideline Group, in severe cases and impairment, 
the use of medication is recommended (Banaschewski et al. 2008). Medications currently 
licensed for the treatment of children and adolescents with ADHD include psychostimulants 
such as methylphenidate hydrochloride (MPH) and dexamfetamine sulphate, and as second 
choice the non-stimulant atomoxetine (ATX). MPH, which reduces the core symptoms of the 
disorder and improves patients’ quality of life, is the first-line treatment for ADHD. Stimulant 
medications are usually titrated until reaching optimal symptom reduction or until significant 
stimulant side effects occur. In the European guidelines of medication for ADHD (Graham et 
al. 2011) it is summarized that side effects occur, but they are generally acceptable because 
they are mild and/or temporary. MPH has a neuropharmacological profile similar to 
amphetamine and cocaine, which are well known as indirect dopamine (DA) agonists that 
cause a striatal DA overflow, probably via DA transporter (DAT) inhibition and partial 
norepinephrine transporter (NET) inhibition (Challman and Lipsky 2000). ATX, a non-
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psychostimulant, is known to act via norepinephrine (NE) reuptake inhibition (Dell'Agnello et 
al. 2009). However, a need for further clarification of the mechanisms of action of the various 
drug therapies still exists. 
The cause and pathophysiology of ADHD is still unknown, but there is clear evidence that 
ADHD has multiple aetiologies (e.g. an interaction of genetic, environmental, 
neurobiological, and neurochemical factors) (Purper-Ouakil et al. 2011). ADHD shows high 
heritability as documented in family, twin, and adoption studies, with estimates of up to a 
70% heredity rate (Faraone and Doyle 2001). To date, although several genome-wide 
association studies (GWAS) and meta-analyses for association studies were conducted, no 
one single nucleotide polymorphism (SNP) or gene was found to be specifically affected in 
ADHD (Zhang et al. 2012). Still, it seems that dopaminergic, serotonergic, noradrenergic, 
synaptic, and growth factors genes are involved in ADHD. Therefore, some functional 
mechanism of action of such genetic findings might reveal the etiopathology of ADHD. 
In vitro studies are one possible route in the quest to find the etiopathology of ADHD as well 
as the mechanism of action of its drug therapy. In vitro analyses span can be applied to cell 
culture studies of vesicular and synaptic release, binding, and electrophysiology analysis. In 
this review, different methods will be applied to ADHD findings, and new techniques will be 
mentioned for future studies of drug or genetic effects in vitro. 
Cell culture studies 
Several studies have been conducted on cell cultures, either non-neuronal transfected cultures 
or neuronal cells (primary/ cell lines) and astrocytic cells in order to elucidate the effects of 
drug therapy or the function of the transporter/ receptor thought to be involved in ADHD. 
Most of these studies involve toxicity /cell viability tests as well as morphological analysis of 
the cells. 
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Non-neuronal culture 
The toxicity effect of MPH was tested on non-neuronal human embryonic kidney (HEK-293) 
cells and HEK-293 cells stably transfected with the human DAT gene (HEK-hDAT) as a 
model limited to the inhibiting effects of MPH on DAT (Ludolph et al. 2006). Ludolph and 
colleagues demonstrated that no toxicity effect could be observed in both HEK-293 and HEK-
hDAT cells treated with MPH at doses of 1-1000M, as measured with an MTT assay (2006). 
In addition, they showed that MPH (250-1000M) reduced cytotoxicity caused by 1-methyl-
4-phenylpyridinium (MPP
+
) in HEK-hDAT cells. In a later study by Schmidt et al., the effect 
of psychostimulants and ATX on cell survival of immune (monocytic U-937) cells was tested 
(2010a). Similar to Ludolph et al.’s study, Schmidt et al. also found increased cell survival, 
while ATP measurements for energy metabolism of the cells revealed no effect what-so-ever 
(2010a). Furthermore, Schmidt and colleagues tested whether psychostimulants and ATX 
affect the transcription of 8-hydroxyguanine glycosylase 1 (hOGG1), which catalyses the 
removal of 8-hydroxy-20-deoxyguanosine (8-oxo-OHdG), one of the predominant products of 
oxidative DNA lesions induced by reactive oxygen species (2010b). After U-937 cell 
treatment with various doses of amphetamine, MPH or ATX, they extracted total RNA for 
reverse-transcription polymerase chain reaction (RT-PCR) for the hOGG1 gene. They 
observed decreased expression of hOGG1 mRNA at a significant level after treatment with 
5000ng/ml amphetamine as well as after treatment with 50, 500 and 5000ng/ml ATX 
(Schmidt et al. 2010b). Therefore, they concluded that these drugs play a protective role 
against oxidative DNA damage. 
In order to learn the functional differences of DA or NE transport blockage, one could use 
transfected cells bearing the DAT or NET. The possibility of whether transporters can 
promote cellular adaptation, analogous to receptors, was raised. In HEK cell lines transfected 
with the hDAT, human DAT, its substrates (DA, amphetamine), and clinically relevant DAT 
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inhibitors (cocaine, MPH and bupropion) reportedly increased c-Fos immunoreactivity (Yatin 
et al. 2002). To demonstrate this novel catecholamine transporter-dependent function, Yatin et 
al. developed an immunofluorescent method to quantify c-Fos in individual cells. Increased 
expression of the immediate early gene c-fos initiates a cascade of intracellular events that 
may underlie neuroadaptive changes following repeated exposure to the drugs. Yatin et al. 
investigated whether substrates (DA, NE) of the human DAT and NET can directly induce c-
Fos protein in HEK cells transfected with hDAT and hNET and whether protein kinase C 
(PKC) modulators affect this process (2005). This group’s demonstration that DA and NE can 
induce c-Fos expression in a monoamine transporter-dependent manner suggests the 
possibility that elevated catecholamine levels induced by psychostimulant drugs of abuse, 
such as cocaine and amphetamine, as well as clinically relevant medications such as MPH and 
bupropion, may affect gene expression and serve as a trigger for neuroadaptive responses in 
neurons expressing monoamine transporters (Yatin et al. 2005).  
Transfected cell cultures are another useful tool in exploring the functional effects of known 
mutations associated with ADHD. For example, the 40-bp variable number of tandem repeats 
(VNTR) polymorphism in the 15
th
 exon of DAT1 (SLC6A3) (Vandenbergh et al., 1992a; 
Vandenbergh et al., 1992b) is known to reside in a region encoding the 3’ untranslated region 
(3’-UTR), which does not alter the protein’s amino acid sequence, but the 10-repeat variant is 
reportedly associated with ADHD (Nemoda et al. 2011). In a study in which HEK cells were 
transfected with four different DAT1 constructs (hDAT, DAT1 coding the region necessary 
and sufficient to produce a functional transporter protein; hDAT Zero, a construct containing 
the DAT1 coding region flanked by an ~800 bp fragment of the 3'-UTR upstream of the 
VNTR region; hDAT 9, a construct with the DAT1 coding region upstream of a full length 3'-
UTR harbouring the 9-repeat VNTR; hDAT 10, a construct with the DAT1 coding region 
upstream of a full length 3'-UTR containing the 10-repeat VNTR), VanNess et al. examined 
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the effects of the DAT1 VNTR on measures of in-vitro DAT expression and pharmacology 
(2005). They were able to demonstrate that DAT expression, as measured using binding 
assays and DAT immunoblotting, is attributed to the DAT1 genotype. Cells carrying the 10-
repeats DAT1 variants were characterised by a Bmax approximately 50% greater than cells 
with the 9-repeat VNTR; those containing only the DAT1 coding region or the coding region 
flanked by a truncated 3'-UTR resulted in greater DAT density than either of the naturalistic 
9- and 10-repeat variants (VanNess et al. 2005). On the other hand, competition binding 
assays showed no statistically significant DAT1 genotype effects on the DAT affinity for 
MPH, as expected (VanNess et al. 2005).  
In studying the transport of drugs into the central nervous system (CNS), Zhu et al. used the 
porcine kidney epithelial cell line LLC-PK1 and its human P-glycoprotein overexpressing 
mutant LLC-PK1/MDR1 cells (2008a). They investigated whether the P-glycoprotein, a 
member of the adenosine triphosphate-binding cassette transporter superfamily that has been 
found in a large number of normal tissues including intestine, liver, placenta, kidney, and the 
blood–brain barrier (BBB), interacts in the drug transport of ATX, MPH, amphetamine, and 
modafinil (Zhu et al. 2008a). Since it is known that in the BBB, P-glycoprotein prohibits 
substrate drug penetration into the CNS (Mayer et al. 1997; van Asperen et al. 1997), Zhu and 
colleagues used intracellular uptake studies with fluorescent substrates doxorubicin and 
rhodamine123 as well as a cell monolayer culture of the transport efficiencies (Zhu et al. 
2008a). Their results demonstrated that all tested agents with the exception of modafinil 
isomers are relatively weak P-glycoprotein inhibitors. Furthermore, P-glycoprotein may play 
a minor role in the transport of d-MPH, d-modafinil, and l-modafinil. The same research 
group established another cell line that stably expressed specific mutation of the human 
carboxylesterase (CES)1 (Zhu et al. 2008b). CES1 is the principal enzyme governing the 
metabolism of MPH and is involved in the metabolism of numerous other therapeutic 
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medications as well as some illicit drugs such as heroin and cocaine. The mutation in exon 4 
of CES1 is located in codon 143 and leads to a non-conservative substitution (Gly143Glu), 
which results in a reduction of enzyme activity and complete loss of hydrolytic activity 
toward methylphenidate. This specific CES1 mutation was also investigated in a Hungarian 
ADHD group (Nemoda et al. 2009), but  no genotype effect could be shown. However, the 
group of Nemoda could detect that carrying the Glu-allele required lower doses of MPH for 
symptom reduction and so it seems that the mutation has an impact on MPH response and 
should be further investigated in larger ADHD samples. 
Neuronal culture 
Similar to the non-neuronal cell culture, the toxic effect of MPH was also tested on primary 
cultures from rat rostral mesencephalic tegmentum (Ludolph et al. 2006). An MTT assay 
demonstrated no toxicity effects of MPH on the neurons, and an additional 
immunocytochemistry and morphological analysis proved no effects on the dopaminergic 
neurons (measured as tyrosine-hydroxylase (TH) positive neurons) (Ludolph et al. 2006). 
MPH has also proved protective effects against MPP
+
 in this cell culture, a result similar to 
the non-neuronal culture (Ludolph et al. 2006). Again, Schmidt et al. tested various 
psychostimulants and ATX for their toxicity effect on human neuroblastoma SH-SY5Y cells 
(2010a). As with the non-neuronal cell culture, MPH and ATX also enhanced cell survival 
(Schmidt et al., 2010a). As described above, in the non-neuronal cell culture, Schmidt et al. 
also demonstrated a decreased hOGG1 mRNA expression after treatment with 
psychostimulants or ATX of the SH-SY5Y cells (2010b).  
Recently, our study group tested the effects of MPH on dopaminergic neuronal cell culture 
devoid of DAT (Bartl et al. 2011). Through this system, we could test MPH effects on the 
cells that are not associated with DAT inhibition. For this study, we used rat 
pheochromocytoma cells (PC12) that do not express DAT, but do express NET. MPH’s 
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influence in a dose response was tested for neurotransmitter levels (release, metabolism, and 
cytoplasmic) using high performance liquid chromatography (HPLC). Gene expression levels 
of synaptic genes were tested using the quantitative RT-PCR (Q-PCR), and cell proliferation 
studies using bromodeoxyuridine (BrdU) were conducted. Treatment with low-dose MPH (1–
100 nM) altered intra-/extracellular neurotransmitter levels, down-regulated all investigated 
genes (NET (SLC6A2), synaptotagmin 1 and 4, syntaxin 1a, and synaptic vesicle glycoprotein 
2C), and significantly enhanced cell proliferation. These data point to the diverse effects of 
MPH on cell metabolism independent of inhibiting DAT (Bartl et al. 2011). This study did 
not investigate the effects of MPH on other uptake systems, for example, organic cation 
transporters (OCT) or plasma membrane monoamine transporter (PMAT). Dwas et al. 
reported in detail that in addition to traditional uptake systems like DAT, NET, or serotonin 
transporter (SERT), OCT and/or PMAT are capable of clearing biogenic amines from 
extracellular fluid and may serve to buffer the effects of frontline antidepressants, MPH and 
amphetamine (Dwas et al. 2009).  The role of OCT in the mechanism of action of MPH is not 
known so far, but it seems to be a very important aspect and, in addition to DAT inhibition, 
should be taken into account for future MPH studies.  
The internalization and recycling of the DAT on the membrane surface was studied since 
PKC was demonstrated to down-regulate DA transport, primarily by redistributing the DAT 
from the plasma membrane to endosomal compartments, which might play an important role 
in treatment with psychostimulants (Loder and Melikian 2003). For this purpose, Loder and 
Melikian used PC12 cells that stably expressed the human DAT (DAT-PC12). For the effects 
of DAT internalisation and recycling, they used cell surface biotinylation and then SDS-
polyacrylamide gel electrophoresis and immunoblotting. In this study, they demonstrate 
constitutive DAT trafficking, and that PKC-mediated DAT sequestration is achieved by a 
combination of accelerated internalisation and reduced recycling (Loder and Melikian 2003).  
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Astrocytes and glial culture 
Since it was reported that astrocytes, which are the most numerous glial cells in the CNS, play 
an important role in the development of synaptic plasticity induced by methamphetamine 
(Miyatake et al. 2005; Narita et al. 2005; Narita et al. 2006), Suzuki et al. investigated 
whether treatment with MPH could affect the morphology of astrocytes, compared to 
methamphetamine (Suzuki et al. 2007). Here, they used limbic neuron/glia co-cultures from 
newborn mice that were treated in a dose response study with MPH or methamphetamine for 
3 days. The effects on activated astrocytes were visualised using fluorescence 
immunocytochemistry with a mouse polyclonal antibody against glial fibrillary acidic protein 
(GFAP). From this study, it can be concluded that treatment with methamphetamine, but not 
MPH, caused long-lasting astrocytic activation in limbic neuron/glia co-cultures. These 
findings suggest that, unlike methamphetamine, MPH induces reversible astrocytic activation 
after washout (Suzuki et al. 2007). Narita and colleagues investigated the involvement of 
phosphatidylinisitol-3 kinase (PI3-K) in astrocyte activation (Narita et al 2009). 
Administration of a selective PI3-K inhibitor wortmannin, together with methamphetamine or 
MPH, markedly and significantly inhibited methamphetamine-/MPH-induced astrocyte 
activation, suggesting the involvement of PI3-K in this process. In primary neuron/glia co-
cultures, a high concentration of methamphetamine dose-dependently reduced the number of 
cells positive for microtubule associated protein 2a/b (MAP2a/b), which is a marker for 
neuronal dendrites; in contrast, MPH treatment did not change the number of MAP2a/b-
positive cells. Narita et al. then measured the immunoreactivity of cleaved caspase-3, which is 
an activated form of apoptosis-related protein caspase-3, in order to reveal whether the 
reduction of MAP2a/b positive cells is due to apoptosis (Narita et al. 2009). They found that a 
high concentration of methamphetamine induced cleaved caspase-3, whereas the same 
treatment with MPH did not induce cleaved caspase-3. The above-mentioned homology 
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between the reduction of MAP2a/b-positive cells and the induction of cleaved caspase-3 
implies that a high concentration of methamphetamine in primary neuron/glia co-cultures 
causes neuronal cell death. In contrast, MPH lacks such an effect. 
Recently, since NE activation of -adrenergic receptors has been observed to induce the 
synthesis of the chemokine monocyte chemoattractant protein (CCL2/MCP-1) in astrocytes, 
the mechanisms involved in this process, particularly the possible effect of NE modulating 
drugs, was tested (Hinojosa-Arango et al. 2009). In this study, the authors used primary rat 
astrocyte cultures treated with NET inhibitors, either desipramine or ATX. The expression 
and synthesis of CCL2/MCP-1 in these cells were investigated using Q-PCR, enzyme-linked 
immunosorbent assay (ELISA), and immunocytochemsitry methodologies. Both drugs 
induced an increase in CCL2/MCP-1 expression in astrocytes (Hinojosa-Arango et al. 2009). 
These results suggest that CCL2/MCP-1 expression could also be modulated by some 
mechanism independent of the elevation of brain NE levels. This was confirmed by 
measuring a reduction in CCL2/MCP-1 production by treatment with clonidine, a 2 
adrenergic receptor agonist. 
Drug binding and transport inhibition 
Since many of the ADHD drug therapies involve inhibition of synaptic DA or NE uptake, 
binding and uptake inhibition potency assays are an important part of drug-effect studies. One 
possibility for such an investigation is using either cell cultures that harbour the transporter of 
interest or using stably transfected cells. These are then used for an uptake assay with a 
radioactive marked substance or for a ligand binding assays using a radioligand and a 
nonradioactive competitor. Such study was conducted by Ukairo et al., who investigated the 
influences on DAT function at the level of the cultured cell by addressing the following: the 
age of the cell line (measured by cell passage number), the density of the cell monolayer (i.e., 
percent confluence), and the effect of varying DAT expression levels by manipulation of 
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transfection conditions (Ukairo et al 2007). To ensure that comparisons between DA uptake 
inhibition potency (DUIP) and apparent binding affinity were legitimate for a given DAT 
inhibitor, [
3
H]-DA uptake assays, binding assays involving the cocaine analogue [
3
H]-WIN 
35,428, and versions of each assay that included competitor nonradioactive DAT blockers 
were conducted under identical conditions. To address, in part, the physiological relevance of 
such a phenomenon, neuronal and non-neuronal cell lines were similarly tested for DAT 
inhibitor DUIP fluctuations. Fluctuations in DUIP were observed for classical DAT blockers 
including cocaine, mazindol, MPH, and benztropine in CHO cells expressing wild type DAT 
(Ukairo et al. 2007). Cocaine potency also decreased in DAT-expressing non-neuronal COS-7 
cells and murine neuroblastoma (N2A) cells (Ukairo et al. 2007). In contrast, the DAT 
substrate amphetamine did not display this DUIP fluctuation. In parallel experiments, no 
fluctuation was observed for the apparent binding affinities of these 5 drugs. The DUIP 
decrease appeared to correlate with an increase in cell surface DAT expression level, as 
measured by Bmax values and confocal microscopy. The fact that the DUIP profile of 
amphetamine diverged from that of the classical DAT blockers is consistent with the idea of 
fundamental differences between the mechanisms of abused psychostimulant DAT substrates 
and inhibitors (Ukairo et al. 2007).  
Such binding and affinity study was also able to demonstrate the differences between the two 
isomers of MPH, the d- and l-threo-isomers (Markowitz et al. 2006; Markowitz and Patrick 
2008). Markowitz et al. demonstrated that MPH has affinity for the serotonergic 5-HT1A and 
5-HT2B receptor sites for both d- and l-MPH, with d-MPH exerting by far the most 
predominant effects (2006; 2009). In addition, they showed a marked difference in affinity to 
NET between the d- and l-isomers, of which d-MPH exhibited prominent affinity.  
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Electrophysiology 
Electrophysiological studies, either on brain slices or single cells using patch clamp with 
electro- or chemical- excitation, are useful tools to investigate the inhibition/activation of 
drugs such as MPH and ATX. For example, MPH was shown to increase cortical excitability 
via activation of 2-noradrenergic receptors (Andrews and Lavin 2006). Similarly, in another 
study, it was demonstrated that the MPH-induced response is probably mediated by NE via 
2B/2C-adrenoceptors in locus coeruleus neurons (Ishimatsu et al. 2002). In a later study, 
whole-cell patch-clamp recordings revealed that MPH enhances inhibitory synaptic 
transmission by increasing the concentration of NE at noradrenergic synapses in juvenile rat 
locus coeruleus neurons (Kidani et al. 2010). On the other hand, in the dopaminergic neurons 
originating from the ventral tegmental areas, Prieto-Gomez and colleagues hypothesised after 
electrophysiological study on brain slices that psychostimulants sensitisation could be 
involved, though both N-Methyl-D-aspartate (NMDA) and kainite/AMPA glutamate 
receptors medicated the excitability of these neurons (Prieto-Gomez et al 2004; 2005).  
ATX has also been studied for its mechanism of action using electrophysiological methods. 
Kobayashi and colleagues investigated the effects of ATX and reboxetine on G-protein-
activated inwardly rectifying K
+
 (GIRK) channels using the Xenopus oocyte expression assay 
(Kobayashi et al 2010). In oocytes injected with mRNA for GIRK1/GIRK2, GIRK2, or 
GIRK1/GIRK4 subunits, an extracellular application of ATX or reboxetine reversibly reduced 
GIRK currents. The inhibitory effects were concentration dependent, but voltage-independent, 
and time-independent during each voltage pulse (Kobayashi et al. 2010). Such findings were 
suggested to point to the therapeutic effects of NET inhibitors and their adverse side effects 
related to the nervous system and heart function. In addition, a recent publication by Ludolph 
et al. demonstrated effective NMDA receptor antagonism by ATX at low micromolar 
concentrations in different cell culture models (Ludolph et al 2010). Therefore, it was 
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proposed that the antagonism at the NMDA receptors by ATX might contribute to the clinical 
effect in ADHD. 
Studies of specific genetic mutations using electrophysiological techniques could also be 
useful in understanding the effects of such mutations on neurotransmitter efflux, as 
demonstrated by Bowton et al. (Bowton et al. 2010). They report that tonic activation of the 
D2 receptor provides support for hDAT A559V-mediated anomalous DA efflux. These studies 
identify a signalling network downstream of D2 receptor activation, normally constraining 
dopaminergic action at synapses that may be altered by DAT mutation to impact risk for 
ADHD. 
Future prospective and methods 
Recently, several new in vitro methods have emerged to be potentially useful in studies 
associated with ADHD genetic mechanisms of action or drug function. Such methods could 
provide additional knowledge for better understanding of the disorder and/or potential targets 
for new therapy developments. 
Stem cells 
Since ADHD is considered a neurodevelopmental disorder, understanding how genes function 
in human brain development and how they interact with each other to cause a psychiatric 
disorder would be of great value. Mouse and human stem cells can teach us a great deal about 
how typical differentiation programs are implemented and how they may be modified in 
disease. But since stem cells are usually derived from embryos, the work with human stem 
cells has been hampered by ethical concerns. One alternative to embryonic stem cells is 
tissue-specific stem cells from adult humans. Stem cells of the central nervous system, from 
the subventricular zone of the cerebral cortex and the subgranular zone of the dentate gyrus, 
are of obvious interest for neuropsychiatric disorders. But again, this is quite limited because 
to harvest such cells, one needs fresh tissue, usually obtained from biopsies. Recently, the 
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enormous advantages of induced pluripotent stem cells (iPSCs), commonly derived from skin 
fibroblasts, have been discussed (see Review, Vaccarino et al. 2011). The fact that such cells 
are derived from a living person using a non-controversial cell type, are generated from a 
specific individual, maintain his/her genetic constitution and diversity, and can represent a 
source of differentiated cell types genetically compatible with the person of origin has great 
advantage. Specifically, examination of iPSCs from typically developing individuals will 
reveal how basic cellular processes and genetic differences contribute to individually unique 
nervous systems. Moreover, by comparing iPSCs from typically developing individuals and 
patients, differences at stem cell stages, through neural differentiation, and into the 
development of functional neurons may be identified that will reveal opportunities for 
intervention. The application of such techniques to early onset neuropsychiatric disorders is 
still on the horizon but has become a reality of current research efforts as a consequence of the 
revelations of many years of basic developmental neurobiological science. 
Impedance-based method of cell proliferation /differentiation monitoring (xCELLigence) 
To date, the cell culture studies for cell viability, cell death, proliferation, or differentiation 
rely on endpoint analysis. Thus, one of the major limitations in the interpretation of such 
analyses in time course is derived from the fact that extensive and laborious endpoint 
measurements in separate cultures are required to cover a sufficient amount of time points for 
interpretation of the kinetic. Therefore, such limitations of standard endpoint assays in vitro 
may be overcome using an impedance-based analysis system for the detection of cell viability 
(xCELLigence, Roche). Consequently, cell populations that differ in cell density, proliferation 
rate, adhesion characteristics, or cell morphology can be distinguished by the impedance 
readout (Xiao et al. 2002). Recently, this system was also tested for detection of neuronal cell 
death and compared to measurements of endpoint viability (Diemert et al. 2012). They could 
validate the xCELLigence system for real-time detection of cell death in a neuronal cell line 
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of immortalised hippocampal neurons (HT-22 cells), neuronal progenitor cells (NPC), and 
differentiated primary cortical neurons (Diemert et al. 2012). They found a good correlation 
between impedance measurements and endpoint viability assays in HT-22 cells and NPC for 
detecting proliferation, cell death kinetics, and also the neuroprotective effects of 
pharmacological apoptosis inhibitors. However, in primary neurons, they could not detect 
dendritic outgrowth during differentiation of the cells. Cell death in primary neurons was 
detectable by the xCELLigence system; however, the changes in the cell index on the basis of 
impedance measurements depend to a great extent on the severity of the insult. Therefore, this 
new method presents great potential in studying cell cultures in a continuous real-time-course 
that can reveal the effects previously missed using conventional methods.  
Live-cell imaging 
The advantages of live-cell imaging have been discussed in many previous reviews 
(Meijering et al. 2009; Tsien 2003). The ability to visualise cells and subcellular dynamic 
processes in space and time has been made possible by revolutionary developments in 
imaging technology in the past two decades. Advances in molecular biology, organic 
chemistry, and materials science have resulted in an impressive toolbox of fluorescent 
proteins (GFP and variants) and nanocrystals (quantum dots) and have enabled the study of 
protein expression, localisation, conformation, diffusion, turnover, trafficking, and interaction 
(Giepmans et al. 2006; Lippincott-Schwartz and Patterson 2003). Hardware advances in 
optical systems design have taken light microscopy from wide field to (multiphoton) confocal 
and spinning disk microscopy (Stephens and Allan 2003), and more recent efforts to break the 
diffraction barrier have further extended the palette (Garini et al. 2005; Hell 2009). Together, 
these developments have redefined biological research by enabling the switch from fixed to 
living cells and from qualitative to quantitative imaging (Tsien 2003).  
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The understanding of synaptic plasticity kinetics will advance neuroscience greatly in regard 
to understanding how neurons store information, how spatiotemporal patterns of synaptic 
input combined with postsynaptic neuronal activity produce neuronal plasticity, and how 
plasticity changes neuronal activity patterns (Kotaleski and Blackwell 2010). Live-cell 
imaging techniques together with new computer modelling may provide much higher 
resolution views into synaptic plasticity (Kotaleski and Blackwell 2010). Similarly, protein 
trafficking dynamics are now available using fluorescently tagged proteins, enabling 
visualisation of protein movements and correlation of a protein’s dynamics with its changing 
structural state or ligand binding (Chamberlain and Hahn 2000). A newly developed 
technique is reported to observe DNA-methylation states in live-cell imaging using 
fluorescent probes that bind specifically to methylated DNA (Yamagata 2010). Such new 
aspects will allow the observation of epigenetic changes due to environmental alterations with 
time, which have not yet been available. Other techniques to visualise synaptic vesicle 
recycling (Kakazu et al. 2012) or the exocytosis of membrane proteins (Hildick et al. 2012) 
were reported to be successful in live-cell imaging. 
To date, few studies using live-cell imaging associated with ADHD have been conducted. 
Still, Bolan et al. investigated the role of two D2 receptor-linked signalling pathways 
(extracellular signal-regulated kinase (ERK1/2) and the PI3-K) in mediating the D2 receptor 
regulation of DAT using the fluorescent DAT substrate 4-(4-(dimethylamino)-styryl)-N-
methylpyridinium (ASP
+
) in live-cell imaging techniques (Bolan et al. 2007). This study 
could show that an increase in DAT function is ERK1/2-dependent but PI3-K-independent, 
which therefore suggests the possibility of a direct physical interaction between DAT and the 
D2 receptor (Bolan et al. 2007). ASP
+
 was also demonstrated to be feasible in analysing the 
function of the serotonin transporter in HEK and neuroblastoma cells (Oz et al. 2010). 
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Conclusion 
Since the aetiology of ADHD is not yet fully revealed, and only some genetic and 
environmental factors that affect the neurodevelopmental processes have been suggested, the 
importance of further research in this field is rather obvious. Psychostimulants (e.g., 
amphetamine, MPH) and non-psychostimulants (e.g., ATX) are used successfully in ADHD 
therapy, but many of their mechanism of action and their adverse effects are not yet fully 
understood. Therefore, both genetic findings and therapeutic effects should be further 
investigated. In conclusion, using in vitro systems to investigate the function of genes 
involved in ADHD or the mechanism of action of drug therapy is a very valuable tool in 
ADHD research. In addition, the new techniques mentioned in this article as well as new to 
come can enhance our understanding of many processes that have not yet been revealed.  
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